Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country

Click to increase image sizeClick to decrease image size

Ethical approval

The Institutional ethics committee approved the study in its present format.

Patient consent

Informed consent was taken from all the patients for participation in a study/report. Additional consent was taken from all patients for off label use of Venetoclax, as it is not yet approved for treatment of AML in India.

Author contributions

Jayastu Senapati and Tulika Seth designed the study, performed the research, analyzed the data and wrote the manuscript. Manoranjan Mahapatra analyzed the data and edited the manuscript. Rishi Dhawan, Pradeep Kumar, Mukul Aggarwal, Jasmita Dass, Ganesh Kumar Vishwanathan and Seema Tyagi edited the manuscript.

Disclosure statement

The authors declare no conflict of interest.

Data availability statement

Data available within the article.